| Conclusions 1.First randomized trial to address the optimal antiplatelet therapy in patients on OAC undergoing coronary stenting 2.In this study whi
{"Image DocumentName": "WOESTConclusions. First randomized trial to address the optimal antiplatelet therapy in patients on OAC undergoing coronary stenting.", "Image ImageDescription": "In this study which was specifically designed to detect bleeding events, the bleeding rate was higher than expected. Primary endpoint was met: OAC plus clopidogrel causes less bleeding than triple antithrombotic therapy, but now shown in a randomized way. Secondary endpoint was met: with double therapy there is no excess of thrombotic/thromboembolic events: stroke, stent thrombosis, target vessel revascularisation, myocardial infarction or death. Less all-cause mortality with double therapy. |", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}